이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Optomed Oyj 관리

관리 기준 확인 3/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Juho Himberg

최고 경영자

€64.0k

총 보상

CEO 급여 비율	81.3%
CEO 임기	less than a year
CEO 소유권	n/a
경영진 평균 재임 기간	5.5yrs
이사회 평균 재임 기간	3.5yrs

최근 관리 업데이트

Recent updates

Earnings Update: Here's Why Analysts Just Lifted Their Optomed Oyj (HEL:OPTOMED) Price Target To €6.63

May 11

Market Might Still Lack Some Conviction On Optomed Oyj (HEL:OPTOMED) Even After 26% Share Price Boost

May 10

Market Might Still Lack Some Conviction On Optomed Oyj (HEL:OPTOMED) Even After 25% Share Price Boost

Mar 22

Earnings Update: Optomed Oyj (HEL:OPTOMED) Just Reported And Analysts Are Trimming Their Forecasts

Feb 18

Market Cool On Optomed Oyj's (HEL:OPTOMED) Revenues

Dec 21

Is Optomed Oyj (HEL:OPTOMED) Using Debt In A Risky Way?

Nov 15

Earnings Update: Optomed Oyj (HEL:OPTOMED) Just Reported And Analysts Are Trimming Their Forecasts

Aug 09

The Optomed Oyj (HEL:OPTOMED) Share Price Has Gained 14% And Shareholders Are Hoping For More

Feb 16

CEO 보상 분석

Juho Himberg 의 보수는 Optomed Oyj 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-€4m
Dec 31 2023	€64k	€52k	-€4m

보상 대 시장: Juho 의 총 보상 ($USD 68.77K ) Finnish 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 338.36K ).

보상과 수익: Juho 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.

CEO

Juho Himberg (54 yo)

less than a year

테뉴어

€64,000

보상

Mr. Juho Himberg is Chief Executive Officer of Optomed Oyj since October 1, 2023. He has served as the CEO of Aidian (former Orion Diagnostica), a leading point-of-care diagnostics company with innovative...

리더십 팀

이름	위치	테뉴어	보상	소유권
Juho Himberg	Chief Executive Officer	less than a year	€64.00k	데이터 없음
Seppo Kopsala	Founder	20.5yrs	€156.00k	데이터 없음
Sakari Knuutti	CFO, Chief Legal Officer & Secretary of the Board	5.5yrs	데이터 없음	데이터 없음

5.5yrs

평균 재임 기간

46yo

평균 연령

경험이 풍부한 관리: OPTOMED 의 관리팀은 노련하고 경험 (평균 재직 기간 5.4 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Seppo Makinen	Independent Director	5.5yrs	€19.00k	0.062% € 66.2k
Reijo Tauriainen	Independent Director	5.5yrs	€19.00k	0.079% € 84.8k
Catherine Calarco	Independent Director	1.2yrs	€19.00k	0.012% € 13.0k
Petri Salonen	Chairman of the Board	18.5yrs	€114.00k	0.077% € 82.8k
Ty Lee	Independent Director	1.2yrs	€19.00k	0.012% € 13.0k
Anna Tenstam	Independent Director	4.1yrs	€19.00k	0.033% € 36.0k
Robert Chang	Member of International Scientific Advisory Board	3.5yrs	데이터 없음	데이터 없음
Nina Hautala	Member of International Scientific Advisory Board	3.5yrs	데이터 없음	데이터 없음
Dan Milea	Member of International Scientific Advisory Board	3.5yrs	데이터 없음	데이터 없음
Tunde Peto	Member of International Scientific Advisory Board	3.5yrs	데이터 없음	데이터 없음
Daniel Ting	Member of International Scientific Advisory Board	3.5yrs	데이터 없음	데이터 없음

3.5yrs

평균 재임 기간

65yo

평균 연령

경험이 풍부한 이사회: OPTOMED 의 이사회는 경험(평균 재직 기간 3.4 년)으로 간주됩니다.

Optomed Oyj 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Optomed Oyj Announces Nomination Board

Optomed Oyj, Annual General Meeting, May 10, 2024

Optomed Announces CEO Transition Plan

Optomed Oyj Approves Board Changes

Mars Duan Has Notifies Optomed plc That He Is Not Available for Re-Election

High number of new and inexperienced directors

Recent updates

Optomed Oyj Provides Revenue Guidance for the Full Year 2024

Earnings Update: Here's Why Analysts Just Lifted Their Optomed Oyj (HEL:OPTOMED) Price Target To €6.63

Price target increased by 14% to €6.63

Forecast to breakeven in 2026

Market Might Still Lack Some Conviction On Optomed Oyj (HEL:OPTOMED) Even After 26% Share Price Boost

First quarter 2024 earnings released: €0.064 loss per share (vs €0.076 loss in 1Q 2023)

New major risk - Share price stability

Optomed Plc Announces Optomed Aurora with AEYE Receives U.S. Food & Drug Administration Clearance in US

Optomed USA, Inc. Introduces Optomed Aurora AEYE

Market Might Still Lack Some Conviction On Optomed Oyj (HEL:OPTOMED) Even After 25% Share Price Boost

Consensus estimates of losses per share improve by 15%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates decrease by 12%

Consensus revenue estimates decrease by 12%

Earnings Update: Optomed Oyj (HEL:OPTOMED) Just Reported And Analysts Are Trimming Their Forecasts

Full year 2023 earnings: EPS and revenues miss analyst expectations

Optomed Oyj Provides Revenue Guidance for the Full Year 2024

Optomed Oyj Announces Nomination Board

Market Cool On Optomed Oyj's (HEL:OPTOMED) Revenues

Is Optomed Oyj (HEL:OPTOMED) Using Debt In A Risky Way?

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Optomed Oyj Provides Revenue Guidance for the Year 2023

Forecast breakeven date moved forward to 2024

Optomed Oyj has completed a Follow-on Equity Offering in the amount of €4.290413 million.

Consensus EPS estimates fall by 15%

Earnings Update: Optomed Oyj (HEL:OPTOMED) Just Reported And Analysts Are Trimming Their Forecasts

New major risk - Share price stability

Optomed Oyj, Annual General Meeting, May 10, 2024

Forecast breakeven date pushed back to 2025

Optomed Announces CEO Transition Plan

Investors Continue Waiting On Sidelines For Optomed Oyj (HEL:OPTOMED)

Optomed Oyj Approves Board Changes

First quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Optomed Plc Provides Revenue Guidance for the Full Year 2023

Price target decreased by 9.9% to €6.37

Forecast breakeven date pushed back to 2025

Full year 2022 earnings: EPS misses analyst expectations

Optomed Oyj Provides Revenue Guidance for the Full Year of 2023

Mars Duan Has Notifies Optomed plc That He Is Not Available for Re-Election

Consensus EPS estimates fall by 12%

High number of new and inexperienced directors

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Optomed Oyj Updates Earnings Guidance for the Full Year 2022

Does Optomed Oyj (HEL:OPTOMED) Have A Healthy Balance Sheet?

Optomed Oyj Announces Board Appointments

Optomed plc Elects Mars Duan to the Board of Directors

Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Optomed Oyj, Annual General Meeting, May 10, 2023

Optomed Plc Announces Resignation of Xisi Guo from Board of Directors, Effective August 19, 2022

Optomed Oyj Announces Resignation of Niina Huikuri as Vice President, Marketing and Member of the Leadership Team

Optomed Oyj Announces Executive Changes

Optomed Oyj Provides Revenue Guidance for the Year 2022

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Optomed Oyj has completed a Follow-on Equity Offering in the amount of €4.822593 million.

Price target decreased to €8.45

No longer forecast to breakeven

High number of new and inexperienced directors

Is Optomed Oyj (HEL:OPTOMED) A Risky Investment?

No longer forecast to breakeven

Price target decreased to €9.95

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Optomed Oyj Provides Revenue Guidance for the Year 2022

Optomed Oyj Announces Correction in Clinical Trial Results

Optomed Oyj to Report Fiscal Year 2021 Results on Mar 04, 2022

Optomed Announces Promising Research Results with Aurora Handheld Fundus Camera

Forecast to breakeven in 2024

Third quarter 2021 earnings released: €0.062 loss per share (vs €0.031 loss in 3Q 2020)

Price target decreased to €12.70

Second quarter 2021 earnings released: €0.065 loss per share (vs €0.083 loss in 2Q 2020)